KR890004704A - Quaternary derivatives of noroxy molarphone which combine nausea and vomiting - Google Patents

Quaternary derivatives of noroxy molarphone which combine nausea and vomiting Download PDF

Info

Publication number
KR890004704A
KR890004704A KR1019870015208A KR870015208A KR890004704A KR 890004704 A KR890004704 A KR 890004704A KR 1019870015208 A KR1019870015208 A KR 1019870015208A KR 870015208 A KR870015208 A KR 870015208A KR 890004704 A KR890004704 A KR 890004704A
Authority
KR
South Korea
Prior art keywords
compound
animal
administered
nausea
vomiting
Prior art date
Application number
KR1019870015208A
Other languages
Korean (ko)
Inventor
아이·골드버그 레온
Original Assignee
자네트 트루바치
유니버시티 오브 시카고
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/092,470 external-priority patent/US4861781A/en
Application filed by 자네트 트루바치, 유니버시티 오브 시카고 filed Critical 자네트 트루바치
Publication of KR890004704A publication Critical patent/KR890004704A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine

Landscapes

  • Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음No content

Description

오심 및 구토를 결감시키는 노르옥시 몰폰의 4급 유도체Quaternary Derivatives of Noroxy Morfon to Deter Nausea and Vomiting

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

Claims (11)

마약성 진통제의 투여로 오심 또는 구토를 일으키기 쉬운 온혈 동물에 마약성 진통제를 투여하기 전 또는 투여와 동시에, 오심 및 구토를 경감시키는 적어도 하나의 하기 일반식의 화합물의 유효량을 투여함을 특징으로 하는 온혈 동물에서의 마약성 진통제의 사용과 관련된 오심 및 구토를 방지 또는 경감시키는 방법.Administering an effective amount of at least one compound of the following general formula to relieve nausea and vomiting to a warm-blooded animal prone to nausea or vomiting with the administration of the narcotic analgesic A method of preventing or alleviating nausea and vomiting associated with the use of narcotic analgesics in warm-blooded animals. 상기 식에서, R은 알릴이거나 또는 클로로알릴, 사이클로 프로필-메틸 또는 프로파길과 같은 관련된 라이칼이며, X는 산의 음이온, 특히 클로라이드, 브로마이드, 요오다이드 또는 메틸설페이트 음이온이다.Wherein R is allyl or a related lycal such as chloroallyl, cyclopropyl-methyl or propargyl, and X is an anion of an acid, in particular a chloride, bromide, iodide or methylsulfate anion. 제1항에 있어서, 화합물을 약 0.05mg/kg 내지 약 1.0mg/kg의 양으로 동물에 투여하는 방법.The method of claim 1, wherein the compound is administered to the animal in an amount of about 0.05 mg / kg to about 1.0 mg / kg. 제1항에 있어서, 화합물을 동물에 경구적으로 투여하는 방법.The method of claim 1, wherein the compound is orally administered to the animal. 제1항에 있어서, 화합물을 동물에 비경구적으로 투여하는 방법.The method of claim 1, wherein the compound is administered parenterally to the animal. 제4항에 있어서, 화합물을 동물에 주사방법으로 투여하는 방법.The method of claim 4, wherein the compound is administered to the animal by injection. 제1항에 있어서, 화합물을 마약성 진통제의 투여 전에 투여하는 방법.The method of claim 1, wherein the compound is administered prior to the administration of the narcotic analgesic. 제6항에 있어서, 화합물을 마약성 진통제를 투여하는 2시간 전까지 동물에게 투여하는 방법.The method of claim 6, wherein the compound is administered to the animal up to 2 hours prior to administering the narcotic analgesic. 제1항에 있어서, 화합물을 마약성 진통제의 투여와 동시에 동물에게 투여하는 방법.The method of claim 1, wherein the compound is administered to the animal simultaneously with the administration of the narcotic analgesic. 제1항에 있어서, 화합물이 메틸날트렉손인 방법.The method of claim 1 wherein the compound is methylnaltrexone. 마약성 진통제의 투여로 오심 또는 구토를 일으키기 쉬운 온혈동물에 마약성 진통제의 투여와 동시에 또는 투여하기 약 2시간 전까지 메틸날트렉손을 약 0.05mg/kg 내지 약 1.0mg/kg의 양으로 투여함을 특징으로 하여 온혈동물에서의 마약성 진통제의 사용과 관련된 오심 및 구토를 방지 또는 경감시키는 방법.Methylnaltrexone is administered in an amount of about 0.05 mg / kg to about 1.0 mg / kg simultaneously with or before the administration of the narcotic analgesic to a warm-blooded animal that is prone to nausea or vomiting with the administration of narcotic analgesics. To prevent or alleviate nausea and vomiting associated with the use of narcotic analgesics in warm-blooded animals. 제10항에 있어서, 메틸날트렉손을 동물에 비경구적으로 투여하는 방법.The method of claim 10, wherein the methylnaltrexone is administered parenterally to the animal. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019870015208A 1987-09-03 1987-12-29 Quaternary derivatives of noroxy molarphone which combine nausea and vomiting KR890004704A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/092,470 US4861781A (en) 1986-03-07 1987-09-03 Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US092470 1987-09-03

Publications (1)

Publication Number Publication Date
KR890004704A true KR890004704A (en) 1989-05-09

Family

ID=22233375

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870015208A KR890004704A (en) 1987-09-03 1987-12-29 Quaternary derivatives of noroxy molarphone which combine nausea and vomiting

Country Status (6)

Country Link
JP (1) JP2625457B2 (en)
KR (1) KR890004704A (en)
CA (1) CA1315689C (en)
DK (1) DK167340B1 (en)
NZ (1) NZ222911A (en)
PH (1) PH22582A (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
EP1615646B2 (en) 2003-04-08 2022-07-27 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
JP5241484B2 (en) 2005-03-07 2013-07-17 ザ ユニヴァーシティー オヴ シカゴ Use of opioid antagonists to attenuate endothelial cell proliferation and endothelial cell migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (en) 2005-05-25 2007-11-14 Progenics Pharm Inc SYNTHESIS OF (R) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
AR057325A1 (en) 2005-05-25 2007-11-28 Progenics Pharm Inc SYNTHESIS OF (S) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
CA2625495A1 (en) * 2005-10-11 2007-04-19 Toray Industries, Inc. Therapeutic agent for nausea and/or vomiting
AU2008233133B2 (en) 2007-03-29 2014-03-27 Progenics Pharmaceuticals, Inc. Crystal forms of (R) -N-methylnaltrexone bromide and uses thereof
PL2565195T3 (en) 2007-03-29 2015-10-30 Wyeth Llc Peripheral opioid receptor and antagonists and uses thereof
TWI553009B (en) 2007-03-29 2016-10-11 普吉尼製藥公司 Peripheral opioid receptor antagonists and uses thereof
CA2694497C (en) * 2007-08-09 2016-07-12 Rensselaer Polytechnic Institute Quaternary opioid carboxamides
KR101581480B1 (en) 2008-02-06 2015-12-30 프로제닉스 파머슈티컬스, 인코포레이티드 Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
US8685995B2 (en) 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof

Also Published As

Publication number Publication date
DK693387D0 (en) 1987-12-30
DK693387A (en) 1989-03-04
DK167340B1 (en) 1993-10-18
JP2625457B2 (en) 1997-07-02
PH22582A (en) 1988-10-17
NZ222911A (en) 1990-11-27
JPS6468376A (en) 1989-03-14
CA1315689C (en) 1993-04-06

Similar Documents

Publication Publication Date Title
KR890004704A (en) Quaternary derivatives of noroxy molarphone which combine nausea and vomiting
US4719215A (en) Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4861781A (en) Quaternary derivatives of noroxymorphone which relieve nausea and emesis
KR900015737A (en) Formulation
CA1200501A (en) Nalbuphine - narcotic analgesic composition and method of producing analgesia
KR920002144A (en) Inflammatory bowel disease prevention and treatment containing zinc L-carnosine salt or its complex as an active ingredient
Ross-Lee et al. Aspirin pharmacokinetics in migraine. The effect of metoclopramide
KR880000098A (en) Chondroitin Sulfate Immunostimulatory Composition
KR950016723A (en) How to suppress autoimmune diseases
Levine et al. Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone
KR950016730A (en) Methods of suppressing vasomotor symptoms and accompanying psychological disorders associated with postmenopausal syndrome
Eddy et al. The analgesic equivalence to morphine and relative side action liability of oxymorphone (4-hydroxydihydromorphinone)
KR920019350A (en) Pharmaceutical Compositions for Autoimmune Disease Therapy
ES2051742T3 (en) QUARTERLY DERIVATIVES OF NOROXI-MORPHINE THAT MITIGATE NAUSEA AND EMESIS.
KR890006644A (en) Crystalline β-lactam Hydrate
KR880007060A (en) Pharmaceutical composition
KR950016735A (en) How to suppress Turner syndrome
KR950016734A (en) Inhibition of sexual prematurity
KR890006227A (en) Phenol-containing antitussive liquid composition
WO1991018606A3 (en) Orally active nonaddicting analgesics
Falk et al. Schedule-induced ***e drinking: Choice between ***e and vehicle
KR930002322A (en) Pyrazole derivatives
KR880009656A (en) Treatment or prophylaxis of local periodontal disease
IE33382L (en) Hexahydroazepines
CA1200499A (en) Synergistic compositions of nalbuphine and non- narcotic analgesic compounds

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application